# Epizyme

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epizyme

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.epizyme.com
- Total disclosed funding: $65M
- Latest round: Series C (Apr 26, 2012)
- Investors on record: 7

## About

Epizyme, Inc. is a biopharmaceutical company focused on the development of innovative therapies for cancer and rare diseases, leveraging epigenetics to address significant unmet medical needs.Epizyme, Inc. was founded in 2007 in Cambridge, US, and is dedicated to creating targeted therapies through epigenetic research. The company underwent a pivotal change when it was acquired by Ipsen Group in June 2022 for USD 247 mn. Prior to this, Epizyme had raised significant funds through various rounds, with the most recent being a Trade Sale in March 2019, amounting to USD 247 mn.Epizyme, Inc. offers a portfolio of transformative medicines primarily targeting oncology and rare diseases. Their flagship products include Tazemetostat, used in the treatment of epithelioid sarcoma and relapsed or refractory follicular lymphoma. The company aims to provide specialized therapies that address high unmet medical needs, focusing on precision medicine to improve patient outcomes.For the year 2021, Epizyme, Inc. reported a revenue of USD 37.43 mn and an EBITDA of USD -230.99 mn, reflecting the company's ongoing investment in research and development to advance its therapeutic offerings.Future growth for Epizyme, Inc. includes plans for the continued development of new treatments targeting various cancers and rare diseases, with a focus on launching new products in the coming years. The company aims to expand its market presence in Europe and Asia by 2024, leveraging the recent funding from Ipsen Group to support its research initiatives and enhance operational capabilities. This strategic direction follows a series of successful fundraising efforts, including the recent acquisition that is planned to bolster their portfolio and operational resources.

## Funding rounds

- Series C, Apr 26, 2012, $25M — New Enterprise Associates
- Series B, Sep 30, 2011, $19M — MPM BioImpact
- Series B, Dec 4, 2009, $6M — Kleiner Perkins, New Enterprise Associates, Bay City Capital, MPM BioImpact, Amgen Inc.
- Series B, Sep 18, 2009, $15M — Kleiner Perkins, Astellas Venture Management, Amgen Ventures, Bay City Capital, MPM BioImpact

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C
- Amgen Inc. — Series B